logo.png
Cabaletta Bio Appoints Anup Marda as Chief Financial Officer
January 23, 2019 08:00 ET | Cabaletta Bio
Mr. Marda joins Cabaletta with 17 years of financial leadership experience RADNOR, Pa., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and...
logo.png
Cabaletta Bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 08:30 ET | Cabaletta Bio
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
logo.png
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cell-Mediated Autoimmune Diseases
January 03, 2019 08:00 ET | Cabaletta Bio
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases, today...
logo.png
Cell Therapy Industry Pioneer, Gwendolyn Binder, Ph.D., to Join Cabaletta Bio Leadership Team
December 12, 2018 08:30 ET | Cabaletta Bio
Dr. Binder is an expert in T cell product development, translational research and GMP manufacturing Joins Cabaletta Bio as Executive Vice President, Science & Technology on February 1, 2019 ...
logo.png
Cabaletta Bio Expands Scientific Regulatory, and Cell Therapy Manufacturing Expertise with Scientific Advisory Board Additions
November 15, 2018 09:00 ET | Cabaletta Bio
-- Carl June, M.D., who led discovery and development of the breakthrough CAR T platform at the University of Pennsylvania -- Jay Siegel, M.D., former head of Office of Therapeutics Research and...
logo.png
Cabaletta Bio Emerges Out of University of Pennsylvania to Develop CAAR T Cell Technology to Treat B Cell-mediated Autoimmune Diseases
November 08, 2018 09:00 ET | Cabaletta Bio
-- Signs exclusive license agreement and multi-year sponsored research agreements with University of Pennsylvania -- Completes $38 million Series A financing to advance lead asset, DSG3-CAART for...